Epigenetics in the Pathogenesis and Treatment of Cutaneous T-Cell Lymphoma

Abstract

Cutaneous T-cell lymphomas (CTCLs) comprise a group of heterogeneous diseases involving malignant T cells. The pathogenesis and etiology of CTCL are still unclear, although a large number of genetic and epidemiological studies on CTCL have been conducted. Most CTCLs have an indolent course, making early diagnosis difficult. Once large-cell transformation occurs, CTCL progresses to more aggressive types, resulting in an overall survival of less than five years. Epigenetic drugs, which have shown certain curative effects, have been selected as third-line drugs in patients with relapsing and refractory CTCL. Many studies have also identified epigenetic biomarkers from tissues and peripheral blood of patients with CTCL and suggested that epigenetic changes play a role in malignant transformation and histone deacetylase inhibitor (HDACi) resistance in CTCL. Single-cell sequencing has been applied in CTCL studies, revealing heterogeneity in CTCL malignant T cells. The mechanisms of HDACi resistance have also been described, further facilitating the discovery of novel HDACi targets. Despite the heterogeneity of CTCL disease and its obscure pathogenesis, more epigenetic abnormalities have been gradually discovered recently, which not only enables us to understand CTCL disease further but also improves our understanding of the specific role of epigenetics in the pathogenesis and treatment. In this review, we discuss the recent discoveries concerning the pathological roles of epigenetics and epigenetic therapy in CTCL.

Advanced Pathogenetic Concepts in T-Cell Prolymphocytic Leukemia and Their Translational Impact

“…TCL1A, MYC, EZH2, AGO2), presenting additional ways of their deregulation beyond the described genomic aberrations. Vice versa, a role of TCL1A/MTCP1 activation and/or ATM inactivation in epigenetic disturbances is also conceivable (47,48).…”

Table_1.xlsx

“…TCL1A, MYC, EZH2, AGO2), presenting additional ways of their deregulation beyond the described genomic aberrations. Vice versa, a role of TCL1A/MTCP1 activation and/or ATM inactivation in epigenetic disturbances is also conceivable (47,48).…”